- Additional Moderna abstracts on pancreatic cancer and NSCLC intismeran trials to be presented at ESMO 2026.
- Moderna schedules investor webcast on October 24 to discuss intismeran clinical data and ESMO 2026 presentations.
Monday, September 21, 2026
Moderna's Phase 3 intismeran melanoma data selected for late-breaking Presidential Symposium at ESMO 2026
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.